Fluicell

Fluicell Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Fluicell (FLUI.ST) as of Nov 20, 2026 is 43.12. In the previous year, Cash Conversion Cycle (CCC) was 627.21 — a change of -93.13% (lower).

Cash Conversion Cycle

43.12

YoY

-93.13%

Last updated:

Cash Conversion Cycle (CCC) of Fluicell is 2025 43.12 . Cash Conversion Cycle (CCC) of Fluicell was 2024 627.21 . It decreases by -93.13% lower compared to the previous year.

The Fluicell Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
79.52 SEK
Jan 1, 2019
-756.47 SEK
Jan 1, 2020
514.86 SEK
Jan 1, 2021
485.48 SEK
Jan 1, 2022
550.19 SEK
Jan 1, 2023
399.11 SEK
Jan 1, 2024
627.21 SEK
Jan 1, 2025
43.12 SEK
The Fluicell Cash Conversion Cycle history
YEARCash Conversion CycleYoY
43.12-93.13%
627.21+57.15%
399.11-27.46%
550.19+13.33%
485.48-5.71%
514.86-168.06%
-756.47-1,051.25%
79.52-69.87%
263.90+131.40%
114.04+341.02%
25.86-97.56%
1,059.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Cash Conversion Cycle (CCC) of Fluicell is 43.12 in 2025.

Cash Conversion Cycle (CCC) of Fluicell changed from 627.21 to 43.12, representing a -93.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Fluicell since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Fluicell with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Fluicell

All Key Metrics — Fluicell